EE200100507A - Hüdroksümatairesinool vähkkasvaja vältimises - Google Patents

Hüdroksümatairesinool vähkkasvaja vältimises

Info

Publication number: EE200100507A
Authority: EE; Estonia
Prior art keywords: hydroxymatairesinol; person; cancer; prevention; administering
Prior art date: 1999-03-30

Application number

EEP200100507A

Other languages

English (en)

Estonian (et)

Inventor

Ahotupa Markku

Eckerman Christer

Kangas Lauri

M�kel� Sari

Saarinen Niina

Santti Risto

W�rri Anni

Original Assignee

Hormos Nutraceutical Oy Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-30

Filing date

2000-03-09

Publication date

2002-12-16

2000-03-09 Application filed by Hormos Nutraceutical Oy Ltd filed Critical Hormos Nutraceutical Oy Ltd

2002-12-16 Publication of EE200100507A publication Critical patent/EE200100507A/xx

Links

206010028980 Neoplasm Diseases 0.000 title abstract 5
UKHWOLNMBQSCLJ-BIENJYKASA-N hydroxymatairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@H]2C(OC[C@@H]2[C@H](O)C=2C=C(OC)C(O)=CC=2)=O)=C1 UKHWOLNMBQSCLJ-BIENJYKASA-N 0.000 title abstract 5
YNOCUODOFOEIFZ-UHFFFAOYSA-N Hydroxymatairesinol Natural products C1=C(O)C(OC)=CC=C1CC1C(=O)OCC1C(O)C1=CC=C(OC)C(O)=C1 YNOCUODOFOEIFZ-UHFFFAOYSA-N 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title abstract 4
230000002265 prevention Effects 0.000 title abstract 3
230000001419 dependent effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000005556 hormone Substances 0.000 abstract 2
229940088597 hormone Drugs 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 abstract 1
HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 abstract 1
235000013305 food Nutrition 0.000 abstract 1
239000002778 food additive Substances 0.000 abstract 1
235000013373 food additive Nutrition 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Botany (AREA)
Heart & Thoracic Surgery (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Mycology (AREA)
Cardiology (AREA)
Gynecology & Obstetrics (AREA)
Biochemistry (AREA)
Pregnancy & Childbirth (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EEP200100507A 1999-03-30 2000-03-09 Hüdroksümatairesinool vähkkasvaja vältimises EE200100507A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/281,094 US6451849B1 (en)	1999-03-30	1999-03-30	Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
PCT/FI2000/000181 WO2000059946A1 (en)	1999-03-30	2000-03-09	Hydroxymatairesinol in cancer prevention

Publications (1)

Publication Number	Publication Date
EE200100507A true EE200100507A (et)	2002-12-16

Family

ID=23075932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100507A EE200100507A (et)	1999-03-30	2000-03-09	Hüdroksümatairesinool vähkkasvaja vältimises

Country Status (25)

Country	Link
US (2)	US6451849B1 (de)
EP (1)	EP1165537B1 (de)
JP (2)	JP4852685B2 (de)
KR (2)	KR100741724B1 (de)
CN (1)	CN1146553C (de)
AT (1)	ATE231500T1 (de)
AU (1)	AU767691B2 (de)
BG (1)	BG65380B1 (de)
BR (1)	BR0007187A (de)
CA (2)	CA2650297C (de)
CZ (2)	CZ301725B6 (de)
DE (1)	DE60001271T2 (de)
DK (1)	DK1165537T3 (de)
EE (1)	EE200100507A (de)
ES (1)	ES2189738T3 (de)
HK (1)	HK1045992B (de)
HU (1)	HUP0200530A3 (de)
MX (1)	MXPA01009714A (de)
NO (4)	NO330135B1 (de)
NZ (1)	NZ512099A (de)
PL (1)	PL199892B1 (de)
RU (1)	RU2241453C2 (de)
SK (2)	SK287749B6 (de)
WO (1)	WO2000059946A1 (de)
ZA (1)	ZA200104440B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6271257B1 (en) *	2000-04-17	2001-08-07	Hormos Nutraceutical Oy Ltd.	Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
WO2002034277A1 (en) *	2000-10-23	2002-05-02	Council Of Scientific And Industrial Research	Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
WO2003016883A1 (en) *	2001-08-16	2003-02-27	Analiza, Inc.	A method of measuring solubility
ES2342713T3 (es) *	2001-11-12	2010-07-13	Analiza, Inc.	Caracterizacion de moleculas.
FI111638B (fi)	2001-11-23	2003-08-29	Hormos Nutraceutical Oy Ltd	Menetelmä hydroksimatairesinolin tuottamiseksi puusta
US7008666B2 (en) *	2001-11-26	2006-03-07	Hormos Nutraceutical Oy Ltd.	Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
FI114022B (fi)	2002-01-17	2004-07-30	Hormos Nutraceutical Oy Ltd	Menetelmä kasvislignaanien valmistamiseksi ja uusi välituote
US20030144216A1 (en) *	2002-01-25	2003-07-31	Mikko Unkila	Method for prevention of diseases in coeliac patients
AU2003201621A1 (en) *	2002-02-05	2003-09-02	Hormos Nutraceutical Oy Ltd	Lignan derivatives
US7048960B2 (en) *	2002-03-22	2006-05-23	Glenn Roy Pizzey	High lignan flaxseed product and product by process
FI20021184A7 (fi)	2002-06-19	2003-12-20	Hormos Medical Ltd	Lignaanivalmisteita
FI114917B (fi) *	2002-08-29	2005-01-31	Hormos Nutraceutical Oy Ltd	Lignaanikomplekseja
FR2851919A1 (fr) *	2003-03-03	2004-09-10	Lmd	Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
US8099242B2 (en)	2003-06-12	2012-01-17	Analiza, Inc.	Systems and methods for characterization of molecules
FI116727B (sv)	2003-11-12	2006-02-15	Arbonova Ab Oy	Ny användning för kvistnötsextrakt
CN1893939B (zh) *	2003-12-26	2011-12-28	农工大Tlo株式会社	用于预防和治疗肝癌的组合物
US7666913B2 (en) *	2004-02-03	2010-02-23	Kotosugi Inc.	Method of treating or preventing osteoporosis using isotaxiresinol derived from Taxus yunnanensis
US20080057140A1 (en) *	2005-01-10	2008-03-06	Mikko Unkila	Use of a Lignan for the Manufacture of a Composition for Preventing or Alleviating of Symptoms Relating to Estrogen Deficiency
US7595078B2 (en) *	2005-03-15	2009-09-29	Glanbia Nutritionals Ireland Limited	Methods of increasing flaxseed hull recovery and resultant flax products
CA2633654A1 (en)	2005-12-19	2008-01-10	Analiza, Inc.	Systems and methods involving data patterns such as spectral biomarkers
DE102006008772A1 (de) *	2006-02-22	2007-08-23	Beiersdorf Ag	Hydroxymatairesinol gegen trockene Haut
DE102006019044A1 (de) *	2006-04-25	2007-10-31	Merck Patent Gmbh	Antioxidantien
FI20106293A0 (fi)	2010-12-06	2010-12-06	Emilia Peuhu	Uudet farmaseuttiset koostumukset
EP2517574B1 (de)	2011-04-29	2015-11-11	Symrise AG	Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer
WO2014025961A1 (en)	2012-08-10	2014-02-13	Analiza, Inc.	Methods and devices for analyzing species to determine diseases
RU2510268C1 (ru) *	2012-11-14	2014-03-27	ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс"	Средство для лечения эстрогензависимых опухолей
AU2015261470A1 (en)	2014-05-15	2016-10-27	Linnea S.A.	Composition comprising 7-hydroxymatairesinol
US9678076B2 (en)	2014-06-24	2017-06-13	Analiza, Inc.	Methods and devices for determining a disease state
CZ2015262A3 (cs) *	2015-04-20	2016-03-16	Výzkumný ústav potravinářský Praha, v.v.i.	Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě
US9669006B2 (en)	2015-07-28	2017-06-06	U.S. Nutraceuticals, LLC	Composition and method to treat and alleviate symptoms of hot flashes in a female subject
CA3008075A1 (en) *	2015-12-09	2017-06-15	Oy Granula Ab Ltd	The use of a composition for lowering cholesterol level in a mammal, a method for its preparation, a composition and a method for preparing food additive comprising said composition
IT201700050994A1 (it)	2017-05-11	2018-11-11	Linnea Sa	Uso di una Composizione comprendente 7-Idrossimatairesinolo
CN118511077A (zh)	2021-10-28	2024-08-16	克利夫兰诊断有限公司	用于确定多种类型的癌症的分配系统和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL80351A (en) *	1986-10-17	1991-12-15	Univ Bar Ilan	Food supplements containing water-soluble plant extracts having antioxidant properties
GB8628228D0 (en) *	1986-11-26	1986-12-31	Inst Biolog Morya Dalnevostoch	Composition inhibiting pathological addiction to alcohol
US4808674A (en) *	1987-08-24	1989-02-28	General Electric Company	Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom
DE4317466A1 (de)	1993-05-26	1994-12-01	Degussa	Verbessertes Verfahren zur Bleiche von Holzstoffen
RU2070037C1 (ru) *	1993-08-10	1996-12-10	Покровский Михаил Владимирович	Способ получения композиции, обладающей гепатопротекторной и кардиопротекторной активностью
RU2066195C1 (ru) *	1994-05-11	1996-09-10	Рендюк Тамара Даниловна	Средство для лечения хронического пиелонефрита
US5585504A (en) *	1994-09-16	1996-12-17	Merck & Co., Inc.	Process of making cox-2 inhibitors having a lactone bridge
DE69521525T2 (de)	1995-10-18	2002-04-25	Kanoldt Arzneimittel Gmbh	Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
AU2100997A (en)	1996-03-08	1997-09-22	Energiser Plc	Composition containing iso-flavonoids and lignans
US5846944A (en)	1996-04-04	1998-12-08	The University Of Saskatchewan	Purified SDG as an antioxidant
JP2987365B1 (ja) *	1998-10-29	1999-12-06	かどや製油株式会社	抗酸化剤
CN1893939B (zh) *	2003-12-26	2011-12-28	农工大Tlo株式会社	用于预防和治疗肝癌的组合物

1999
- 1999-03-30 US US09/281,094 patent/US6451849B1/en not_active Expired - Lifetime
2000
- 2000-03-09 DE DE60001271T patent/DE60001271T2/de not_active Expired - Lifetime
- 2000-03-09 AU AU31692/00A patent/AU767691B2/en not_active Ceased
- 2000-03-09 CA CA2650297A patent/CA2650297C/en not_active Expired - Fee Related
- 2000-03-09 SK SK5010-2009A patent/SK287749B6/sk not_active IP Right Cessation
- 2000-03-09 JP JP2000609455A patent/JP4852685B2/ja not_active Expired - Fee Related
- 2000-03-09 HK HK02107351.6A patent/HK1045992B/zh not_active IP Right Cessation
- 2000-03-09 PL PL350367A patent/PL199892B1/pl unknown
- 2000-03-09 WO PCT/FI2000/000181 patent/WO2000059946A1/en not_active Ceased
- 2000-03-09 MX MXPA01009714A patent/MXPA01009714A/es active IP Right Grant
- 2000-03-09 KR KR1020017012487A patent/KR100741724B1/ko not_active Expired - Fee Related
- 2000-03-09 ES ES00909388T patent/ES2189738T3/es not_active Expired - Lifetime
- 2000-03-09 BR BR0007187-0A patent/BR0007187A/pt not_active Application Discontinuation
- 2000-03-09 CZ CZ20013486A patent/CZ301725B6/cs not_active IP Right Cessation
- 2000-03-09 SK SK1326-2001A patent/SK287001B6/sk not_active IP Right Cessation
- 2000-03-09 EP EP00909388A patent/EP1165537B1/de not_active Expired - Lifetime
- 2000-03-09 RU RU2001129166/15A patent/RU2241453C2/ru not_active IP Right Cessation
- 2000-03-09 AT AT00909388T patent/ATE231500T1/de active
- 2000-03-09 HU HU0200530A patent/HUP0200530A3/hu unknown
- 2000-03-09 CN CNB008055424A patent/CN1146553C/zh not_active Expired - Fee Related
- 2000-03-09 CA CA2371839A patent/CA2371839C/en not_active Expired - Fee Related
- 2000-03-09 DK DK00909388T patent/DK1165537T3/da active
- 2000-03-09 CZ CZ20100072A patent/CZ302730B6/cs not_active IP Right Cessation
- 2000-03-09 KR KR1020077003673A patent/KR100741723B1/ko not_active Expired - Fee Related
- 2000-03-09 NZ NZ512099A patent/NZ512099A/xx not_active IP Right Cessation
- 2000-03-09 EE EEP200100507A patent/EE200100507A/xx unknown
2001
- 2001-04-11 US US09/829,944 patent/US20010016590A1/en not_active Abandoned
- 2001-05-30 ZA ZA200104440A patent/ZA200104440B/en unknown
- 2001-08-30 BG BG105856A patent/BG65380B1/bg unknown
- 2001-09-25 NO NO20014639A patent/NO330135B1/no not_active IP Right Cessation
2010
- 2010-07-27 NO NO20101067A patent/NO331188B1/no not_active IP Right Cessation
- 2010-12-06 NO NO20101701A patent/NO332110B1/no not_active IP Right Cessation
- 2010-12-16 JP JP2010280712A patent/JP2011052024A/ja active Pending
2011
- 2011-09-23 NO NO20111291A patent/NO332251B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2189738T3 (es)	2003-07-16
SK287749B6 (sk)	2011-08-04
BG105856A (bg)	2002-04-30
MXPA01009714A (es)	2003-06-24
NO332251B1 (no)	2012-08-06
AU3169200A (en)	2000-10-23
ATE231500T1 (de)	2003-02-15
JP2002541158A (ja)	2002-12-03
KR100741724B1 (ko)	2007-07-23
SK287001B6 (sk)	2009-09-07
PL350367A1 (en)	2002-12-02
CA2371839A1 (en)	2000-10-12
CN1146553C (zh)	2004-04-21
CZ20013486A3 (cs)	2002-02-13
WO2000059946A8 (en)	2001-01-25
CZ301725B6 (cs)	2010-06-02
CA2650297A1 (en)	2000-10-12
DE60001271D1 (de)	2003-02-27
HK1045992A1 (en)	2002-12-20
SK13262001A3 (sk)	2002-02-05
CA2650297C (en)	2012-05-15
KR20010108434A (ko)	2001-12-07
NO20014639D0 (no)	2001-09-25
BG65380B1 (bg)	2008-05-30
HUP0200530A2 (hu)	2002-07-29
NO20101067L (no)	2001-09-25
NO20014639L (no)	2001-09-25
DK1165537T3 (da)	2003-05-12
NO20101701L (no)	2001-09-25
KR20070027770A (ko)	2007-03-09
EP1165537A1 (de)	2002-01-02
CA2371839C (en)	2011-10-04
US20010016590A1 (en)	2001-08-23
KR100741723B1 (ko)	2007-07-23
NO331188B1 (no)	2011-10-31
NO330135B1 (no)	2011-02-21
HUP0200530A3 (en)	2002-10-28
CZ302730B6 (cs)	2011-10-05
NO20111291L (no)	2001-09-25
RU2241453C2 (ru)	2004-12-10
JP2011052024A (ja)	2011-03-17
NZ512099A (en)	2004-01-30
BR0007187A (pt)	2002-02-19
ZA200104440B (en)	2002-07-30
AU767691B2 (en)	2003-11-20
NO332110B1 (no)	2012-06-25
WO2000059946A1 (en)	2000-10-12
PL199892B1 (pl)	2008-11-28
DE60001271T2 (de)	2003-07-31
JP4852685B2 (ja)	2012-01-11
US6451849B1 (en)	2002-09-17
EP1165537B1 (de)	2003-01-22
CN1345315A (zh)	2002-04-17
HK1045992B (zh)	2005-02-25

Publication	Publication Date	Title
DE60001271D1 (de)	2003-02-27	Hydroxymatairesinol in der krebs-prevention
IL130931A0 (en)	2001-01-28	Small molecules useful in the treatment of inflammatory disease
IS1907B (is)	2003-12-16	Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
WO2001036640A3 (en)	2001-10-11	Human fgf-21 gene and gene expression products
BG103740A (en)	2000-05-31	Phytostyrene composition for the prevention of the alzheimer's disease
DE60235719D1 (de)	2010-04-29	Frauenhygieneartikel zur verabreichung von arzneimittel
IL175158A0 (en)	2006-09-05	Tocopherol-modified therapeutic drug compounds
ATE556706T1 (de)	2012-05-15	Fettalkohol-arzneimittel-konjugate
NO20015584L (no)	2002-01-03	Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
WO1999029729A3 (en)	1999-07-15	Antagonists of neuropilin receptor function and use thereof
WO2002040702A3 (en)	2004-01-08	Methods for the treatment of cancer and other diseases and methods of developing the same
BR0110837A (pt)	2003-03-11	Quimioterapia de combinação
DE69726712D1 (de)	2004-01-22	Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
IL146125A0 (en)	2002-07-25	Novel quinones as disease therapies
WO2001076638A3 (en)	2002-05-16	Compositions for drug delivery
WO2000001729A3 (en)	2000-02-10	Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
AUPP823999A0 (en)	1999-02-11	A treatment
WO2003080800A3 (en)	2004-01-15	Prevention and treatment of disease using angiogenesis-and/or tumor antigens
DE60037402D1 (de)	2008-01-24	Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng
NZ514691A (en)	2004-02-27	Method to type prion proteins
RU95120677A (ru)	1998-02-10	Способ лечения злокачественных опухолей
IT1277118B1 (it)	1997-11-04	Composizioni farmaceutiche per il trattamento delle epatopatie croniche
NZ517348A (en)	2002-09-27	Use of a mycobacterial extract in the treatment of inflammatory bowel disease
UA28489A (uk)	2000-10-16	Спосіб лікування затримки статевого розвитку у хлопцівпідлітків
MD1780G2 (ro)	2002-05-31	Metodă de tratament al pacienţilor cu ciroze hepatice